Skip to content
Open access · CC-BY via OpenAlex

Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence

Weinian Liao, Fangze Shao, Shaoyan Wang, Yetong Wang, Xinliang Chen, Yue Zhang, Zhang Zhang, Xiaodong Zai, Yilong Yang, Ying Yin, Youliang Wang, Jun Zhang, Junping Wang, Junjie Xu

Signal Transduction and Targeted Therapy · 2026

Abstract

Immunosenescence represents a central hallmark of organismal aging, characterized by a progressive decline in immune function, which compromises host defense and accelerates systemic aging. Hematopoietic stem cell (HSC) aging is a key contributor to this process, characterized by aberrant expansion, myeloid-biased differentiation, and impaired self-renewal, culminating in hematopoietic-immune imbalance. Although the expansion and survival advantages of aged HSCs have been well-demonstrated, the underlying mechanisms remain elusive. Here, we reveal that regulatory T cells (Tregs) within the bone marrow (BM) microenvironment actively safeguard the survival of aged HSCs via a previously uncharacterized signaling pathway. We identify a novel aged HSC subpopulation characterized by high expression of Baculoviral IAP Repeat Containing 6 (BIRC6), an apoptosis inhibitor. This BIRC6-high subpopulation is markedly expanded in aged mice and recapitulates the hallmarks of HSC aging. Mechanistically, cAMP derived from BM Tregs activates the PKA-CREB pathway in HSCs, activating Birc6 transcription, which reduces apoptotic priming in aged HSCs, thereby promoting hematopoietic-immune imbalance. Strikingly, targeted BIRC6 inhibition in HSCs using antibody-conjugated lipid nanoparticle-encapsulated antisense oligonucleotides (LNP-ASOs) significantly reverses hematopoietic-immune aging phenotypes and ameliorates age-associated immune dysfunction in middle-aged mice. LNP-ASO treatment dramatically rebalances immune cell production, reduces immunosenescence markers, and enhances vaccine responses in middle-aged mice. More importantly, this strategy was also effective in HSCs from middle-aged human donors, highlighting its potential for clinical translation. These findings elucidate a key microenvironmental pathway (Treg-cAMP-PKA-CREB-BIRC6) driving HSC aging and offer a novel strategy to ameliorate the aged hematopoietic system and combat age-related immune decline.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1038/s41392-026-02787-1
Canonical
link ↗
Fetched
2026-10-24 MST

Cite this

APA
Liao, W., Shao, F., Wang, S., Wang, Y., Chen, X., Zhang, Y., Zhang, Z., Zai, X., Yang, Y., Yin, Y., Wang, Y., Zhang, J., Wang, J., &amp; Xu, J. (2026). Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence. <em>Signal Transduction and Targeted Therapy</em>. https://doi.org/10.1038/s41392-026-02787-1
Vancouver
Liao W, Shao F, Wang S, Wang Y, Chen X, Zhang Y, et al. Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence. Signal Transduction and Targeted Therapy. 2026. doi:10.1038/s41392-026-02787-1.
BibTeX
@article{weinian2026Target, title = {Targeting BIRC6 rejuvenates hematopoietic stem cell aging and immunosenescence}, author = {Weinian Liao and Fangze Shao and Shaoyan Wang and Yetong Wang and Xinliang Chen and Yue Zhang and Zhang Zhang and Xiaodong Zai and Yilong Yang and Ying Yin and Youliang Wang and Jun Zhang and Junping Wang and Junjie Xu}, journal = {Signal Transduction and Targeted Therapy}, year = {2026}, doi = {10.1038/s41392-026-02787-1}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings